3′ UTR of the human prohibitin gene

Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0



Reexamination Certificate



The 3′ untranslated region of the human prohibitin gene has been isolated for use in a cancer susceptibility screen and as a therapeutic agent for the treatment of cancer.

patent: 5401635 (1995-03-01), Nakamura et al.
patent: 5776738 (1998-07-01), Dell Orco
patent: 5922852 (1999-07-01), Dell'Orco et al.
patent: WO96/40919 (1996-12-01), None
Sequence alignment between Seq ID No. 3 and Seq ID No. 10.
Asamoto, M. and Cohen, S.M., “Prohibitin gene is overexpressed but not mutated in rat bladder carcinomas and cell lines”Cancer Let83:201-207 (1994).
Black, D. and Solomon, E., “The search for the familial breast/ovarian cancer gene,”Trends in Genetics9:22-26 (1993).
Black, et al., “A somatic cell hybrid map of the long arm of human chromosome 17, containing the familial breast cancer locus (BRCAI),”Am J Hum Genet52:702-710 (1993).
Castilla, et al., “Mutations in theBRCA1gene in families with early-onset breast and ovarian cancer,”Nature Genetics8:387-391 (1993).
Choongkittaworn, et al., “Expression of prohibitin in rat seminiferous epithelium,”Biology of Reproduction49:300-310 (1993).
Cliby, et al., “Absence of prohibitin gene mutations in human epithelial ovarian tumors,”Gynecologic Oncology50:34-37 (1993).
Davis, S. and Watson, J.S., “In vitro activation of the interferon-induced, double-stranded RNA-dependent protein kinase PKR by RNA from the 3′ untranslated regions of human α-tropomyosin,”Proc Natl Acad Sci USA93:508-513 (1996).
Deisseroth, et al., “Genetic therapy of human neoplastic disease,”Proc Am Assoc Cancer Res36:655-656 (1995).
Gross-Bellard, et al., “Isolation of high-molecular-weight DNA from mammalian cells,”Eur J Biochem36:32-38 (1973).
Holmes D.S. and Quigley, M., “A rapid boiling method for the preparation of bacterial plasmids,”Anal Biochem114:193-197 (1981).
Hongyo, et al., “‘Cold SSCP’: a simple, rapid and nonradioactive method for optimized single-strand conformation polymorphism analyses,”Nuc Acids Res21:3637-3642 (1993).
Internal Medicine, 4th edition; editor-in-chief Jay Stein, pp. 699-715.
Jupe, et al., “Lack of heterozygosity for prohibitin in breast cancer cell lines,”Proc Am Assoc Cancer Res36:569 (abstract 3390) (1995).
Jupe, et al., “Prohibitin antiproliferative activity and lack of heterozygosity in immortalized cell lines,”Exp Cell Res218:577-580 (1995).
Jupe, et al., “The loss of prohibitin's tumor suppressor activity in breast cancer is associated with mutations in its 3′ untranslated region,”48th Annual Symposium on Fundamental Cancer Research. Genetic Mechanisms of Cancer, Abstract C-62, Oct. 17-20, 1995.
Jupe, et al., “Prohibitin and breast cancer susceptibility,”35th Annual Meeting of The American Society for Cell Biology, Abstract 2008, p. 346a, Dec. 13, 1995.
Jupe, et al., “The 3′ untranslated region of prohibitin and cellular immortalization,”Experimental Cell Res224:128-135 (1996).
Jupe, et al., “Mutations in the 3′ untranslated region (3′ UTR) of prohibitin are related to loss of function and are diagnostic for breast cancer,”Proc Am Assoc Cancer Res37:583, Abstract 4000 (1996).
Jupe, et al., “Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3′ untranslated region mutation,”Cell Growth&Differentiation7:871-878 (1996).
Liu, et al., “Prohibitin expression during cellular senescence of human diploid fibroblasts,”Biochem Biophys Res Comm201:409-414 (1994).
Manjeshwar, et al., “Prohibitin as a diagnostic for breast cancer susceptibility and tumor development in stained slides of tissue section,”Proc Am Assoc Cancer Res37:257, Abstract 1751 (1996).
McClung, et al., “Isolation of a cDNA hybrid selects antiproliferative mRNA from rat liver,”Biochem Biophys Res Comm164:1316-1322 (1989).
Nuell, et al., “Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells,”Mol Cell Biol11:1372-1381 (1991).
Orkin, et al., “Report and recommendation of the panel to assess the NIH investment in research on gene therapy,” issued by National Institutes of Health (1995).
Sato, et al., “The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer,”Cancer Res52:1643-1646 (1992).
Suggs, et al., “Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human β2-microglobulin,”Proc Natl Acad Sci78:6613-6617 (1981).
Terashima, et al., “The IgM antigen receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein,”EMBO J13:3782-3892 (1994).
Tokino, et al., “Absence of germline prohibitin mutations in early onset breast cancer,”International J Oncology3:769-772 (1993).
White, et al., “Assignment of the human prohibitin gene (PHB) to chromosome 17 and identification of a DNA polymorphism,”Genomics11:228-230 (1991).
Rastinejad, et al., “Tumor suppression by RNA from the 3′ untranslated region of α-tropomyosin,”Cell75:1107-1117 (1993).
Saiki, et al., “Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia,”Science230:1350-1354 (1985).
Sato, et al., “The human prohibitin (PHB) gene family and its somatic mutations in human tumors,”Genomics17:762-764 (1993).


Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.


3′ UTR of the human prohibitin gene does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3′ UTR of the human prohibitin gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3′ UTR of the human prohibitin gene will most certainly appreciate the feedback.

Rate now


Profile ID: LFUS-PAI-O-3830542

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.